We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why
Read MoreHide Full Article
Key Takeaways
Kiniksa Pharmaceuticals posted 55% growth in Arcalyst revenues to $457.9 million in first-half 2026.
Kiniksa Pharmaceuticals raised 2026 Arcalyst revenue guidance to $980-$995 million.
KPL-387 is advancing in phase III as a potential monthly-dosed treatment for recurrent pericarditis.
Shares of Kiniksa Pharmaceuticals International (KNSA - Free Report) have soared 41% over the past three months, driven by strong sales growth from its leading commercial product, Arcalyst, upward revisions to the company’s 2026 revenue outlook and encouraging progress across its next-generation pipeline.
Strong Arcalyst Sales Performance in Q2
Kiniksa Pharmaceuticals continues to benefit from the strong commercial performance of Arcalyst. The therapy is FDA-approved for recurrent pericarditis, cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and muckle-wells syndrome and deficiency of IL-1 receptor antagonist.
In the second quarter of 2026, Arcalyst net product revenues rose 55% year over year to $243.6 million, while sales increased 14% sequentially. For the first six months of 2026, product revenues reached $457.9 million, up 55% year over year, underscoring the product's strong commercial momentum.
Arcalyst’s strength has prompted Kiniksa Pharmaceuticals to raise its 2026 revenue outlook multiple times. The company initially projected net product revenues of $900-$920 million, later increased the range to $930-$945 million in the first quarter and raised it again in the second quarter to $980-$995 million. The latest forecast puts Arcalyst within reach of the $1 billion annual revenue milestone, reinforcing investor confidence in Kiniksa Pharmaceuticals' ability to generate sustained growth.
The company is expanding Arcalyst's global reach through its partnership with Huadong Pharmaceutical in China and continues to strengthen manufacturing capabilities while exploring additional indications, including cardiac sarcoidosis.
Year to date, KNSA shares have surged 88.1% compared with the industry’s 6.5% growth.
Image Source: Zacks Investment Research
KNSA’s Pipeline Assets Are on the Move
Kiniksa Pharmaceuticals is not relying solely on Arcalyst to sustain its long-term relevance in recurrent pericarditis. The company is developing new IL-1-targeted therapies to complement the Arcalyst franchise. The key pipeline candidate is KPL-387, which is currently being evaluated in the pivotal phase III PASTORALE study. The study is actively enrolling and dosing patients with recurrent pericarditis.
The candidate is being developed as a potential next-generation treatment that could offer a more convenient monthly dosing schedule. In late July, the company announced interim data from the phase II portion of the study, which demonstrated rapid and sustained reductions in pain and inflammation at a 300-mg once-monthly subcutaneous dose of KPL-387. Based on the results, the 300-mg monthly dose was selected as the dosing regimen for the phase III study. If successful, KPL-387 could provide another product within Kiniksa Pharmaceuticals’ core cardiovascular franchise and potentially broaden the market for IL-1α/IL-1β inhibition. The company expects the new treatment option to reach patients around 2028/2029.
Another pipeline candidate, KPL-1161, is an Fc-modified monoclonal antibody that acts as an IL-1 receptor antagonist and is designed for quarterly subcutaneous dosing. The candidate is currently in preclinical development, with a phase I first-in-human study expected to commence by the end of 2026.
Kiniksa Pharmaceuticals International, plc Price and Consensus
Over the past 60 days, estimates for Precigen’s 2026 bottom line have improved from a loss of 2 cents to earnings per share of 25 cents. Over the same period, earnings estimates for 2027 have risen from 25 cents to 86 cents. PGEN shares have increased 77.9% year to date.
Precigen’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 108.96%.
Over the past 60 days, estimates for AC Immune’s 2026 loss per share have narrowed from 84 cents to 60 cents. Over the same period, earnings estimates for 2027 remained unchanged at 17 cents. ACIU shares have lost 15.6% year to date.
AC Immune’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 33.25%.
Over the past 60 days, loss per share estimates for Aldeyra Therapeutics have narrowed from 43 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have narrowed from 22 cents to 16 cents. ALDX shares have plunged 73.6% year to date.
Aldeyra Therapeutics’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 29.25%.
View the Zacks #1 Rank List
Image: Bigstock
Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why
Key Takeaways
Shares of Kiniksa Pharmaceuticals International (KNSA - Free Report) have soared 41% over the past three months, driven by strong sales growth from its leading commercial product, Arcalyst, upward revisions to the company’s 2026 revenue outlook and encouraging progress across its next-generation pipeline.
Strong Arcalyst Sales Performance in Q2
Kiniksa Pharmaceuticals continues to benefit from the strong commercial performance of Arcalyst. The therapy is FDA-approved for recurrent pericarditis, cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and muckle-wells syndrome and deficiency of IL-1 receptor antagonist.
In the second quarter of 2026, Arcalyst net product revenues rose 55% year over year to $243.6 million, while sales increased 14% sequentially. For the first six months of 2026, product revenues reached $457.9 million, up 55% year over year, underscoring the product's strong commercial momentum.
Arcalyst’s strength has prompted Kiniksa Pharmaceuticals to raise its 2026 revenue outlook multiple times. The company initially projected net product revenues of $900-$920 million, later increased the range to $930-$945 million in the first quarter and raised it again in the second quarter to $980-$995 million. The latest forecast puts Arcalyst within reach of the $1 billion annual revenue milestone, reinforcing investor confidence in Kiniksa Pharmaceuticals' ability to generate sustained growth.
The company is expanding Arcalyst's global reach through its partnership with Huadong Pharmaceutical in China and continues to strengthen manufacturing capabilities while exploring additional indications, including cardiac sarcoidosis.
Year to date, KNSA shares have surged 88.1% compared with the industry’s 6.5% growth.
Image Source: Zacks Investment Research
KNSA’s Pipeline Assets Are on the Move
Kiniksa Pharmaceuticals is not relying solely on Arcalyst to sustain its long-term relevance in recurrent pericarditis. The company is developing new IL-1-targeted therapies to complement the Arcalyst franchise. The key pipeline candidate is KPL-387, which is currently being evaluated in the pivotal phase III PASTORALE study. The study is actively enrolling and dosing patients with recurrent pericarditis.
The candidate is being developed as a potential next-generation treatment that could offer a more convenient monthly dosing schedule. In late July, the company announced interim data from the phase II portion of the study, which demonstrated rapid and sustained reductions in pain and inflammation at a 300-mg once-monthly subcutaneous dose of KPL-387. Based on the results, the 300-mg monthly dose was selected as the dosing regimen for the phase III study. If successful, KPL-387 could provide another product within Kiniksa Pharmaceuticals’ core cardiovascular franchise and potentially broaden the market for IL-1α/IL-1β inhibition. The company expects the new treatment option to reach patients around 2028/2029.
Another pipeline candidate, KPL-1161, is an Fc-modified monoclonal antibody that acts as an IL-1 receptor antagonist and is designed for quarterly subcutaneous dosing. The candidate is currently in preclinical development, with a phase I first-in-human study expected to commence by the end of 2026.
Kiniksa Pharmaceuticals International, plc Price and Consensus
Kiniksa Pharmaceuticals International, plc price-consensus-chart | Kiniksa Pharmaceuticals International, plc Quote
KNSA’s Zacks Rank & Stock to Consider
Kiniksa Pharmaceuticals currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Precigen (PGEN - Free Report) , currently sporting a Zacks Rank #1 (Strong Buy), and AC Immune (ACIU - Free Report) and Aldeyra Therapeutics (ALDX - Free Report) , carrying a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Precigen’s 2026 bottom line have improved from a loss of 2 cents to earnings per share of 25 cents. Over the same period, earnings estimates for 2027 have risen from 25 cents to 86 cents. PGEN shares have increased 77.9% year to date.
Precigen’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 108.96%.
Over the past 60 days, estimates for AC Immune’s 2026 loss per share have narrowed from 84 cents to 60 cents. Over the same period, earnings estimates for 2027 remained unchanged at 17 cents. ACIU shares have lost 15.6% year to date.
AC Immune’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 33.25%.
Over the past 60 days, loss per share estimates for Aldeyra Therapeutics have narrowed from 43 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have narrowed from 22 cents to 16 cents. ALDX shares have plunged 73.6% year to date.
Aldeyra Therapeutics’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 29.25%.